2 results
Approved WMOCompleted
Primary objectives:• To evaluate the safety and tolerability of BMS-914143 as measured by the frequency of SAEs and discontinuations due to AEs;• To assess the HBeAg seroconversion rate at 24 weeks off treatment (Week 72).Secondary objective• To…
Approved WMOCompleted
The central question of this study is *What is the effect of supplementation of regular therapy with 8 weeks of HR after a first, acute, proximal DVT of the lower extremity on objective aspects of thrombus resolution which are associated with the…